13 August 2019
By Dr Wendy Winnall - PCFA Research Team
Radiotherapy for prostate cancer is constantly being improved. Some of these modifications involve giving a higher dose of radiation over a shorter time-period. Although the outcomes are similar, this reduces the number of treatments for the patient and frees up healthcare resources. This week’s blog describes the latest clinical trial results for ultra-hypofractionated radiotherapy for prostate cancer.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
